Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia

Nur Afiqah Mohamad, Vasudevan Ramachandran, Patimah Ismail, Hazlita Mohd Isa, Yoke Mun Chan, Nor Fariza Ngah, Norshakimah Md Bakri, Siew Mooi Ching, Fan Kee Hoo, Wan Aliaa Wan Sulaiman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

● AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. ● METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. ● RESULTS: The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001). ● CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.

Original languageEnglish
Pages (from-to)1889-1897
Number of pages9
JournalInternational Journal of Ophthalmology
Volume10
Issue number12
DOIs
Publication statusPublished - 18 Dec 2017

Fingerprint

Malaysia
Photochemotherapy
Tertiary Healthcare
Macular Degeneration
Retinal Diseases
Therapeutics
Ranibizumab
Eye Diseases
Electronic Health Records
Ophthalmology
Tertiary Care Centers
Software
Logistic Models
Demography
Databases
Injections

Keywords

  • Anti-vascular endothelial growth factor therapy
  • Photodynamic therapy
  • Ranibizumab
  • Treatment patterns

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Mohamad, N. A., Ramachandran, V., Ismail, P., Mohd Isa, H., Chan, Y. M., Ngah, N. F., ... Wan Sulaiman, W. A. (2017). Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia. International Journal of Ophthalmology, 10(12), 1889-1897. https://doi.org/10.18240/ijo.2017.12.16

Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia. / Mohamad, Nur Afiqah; Ramachandran, Vasudevan; Ismail, Patimah; Mohd Isa, Hazlita; Chan, Yoke Mun; Ngah, Nor Fariza; Md Bakri, Norshakimah; Ching, Siew Mooi; Hoo, Fan Kee; Wan Sulaiman, Wan Aliaa.

In: International Journal of Ophthalmology, Vol. 10, No. 12, 18.12.2017, p. 1889-1897.

Research output: Contribution to journalArticle

Mohamad, NA, Ramachandran, V, Ismail, P, Mohd Isa, H, Chan, YM, Ngah, NF, Md Bakri, N, Ching, SM, Hoo, FK & Wan Sulaiman, WA 2017, 'Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia', International Journal of Ophthalmology, vol. 10, no. 12, pp. 1889-1897. https://doi.org/10.18240/ijo.2017.12.16
Mohamad, Nur Afiqah ; Ramachandran, Vasudevan ; Ismail, Patimah ; Mohd Isa, Hazlita ; Chan, Yoke Mun ; Ngah, Nor Fariza ; Md Bakri, Norshakimah ; Ching, Siew Mooi ; Hoo, Fan Kee ; Wan Sulaiman, Wan Aliaa. / Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia. In: International Journal of Ophthalmology. 2017 ; Vol. 10, No. 12. pp. 1889-1897.
@article{24f9fb458ea24dc3ba7bc94801150ccf,
title = "Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia",
abstract = "● AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. ● METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. ● RESULTS: The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1{\%}) and a higher number of Chinese (47.4{\%}) patients. Among the 821 patients, 62.9{\%} received ranibizumab injection followed by 19.2{\%} PDT therapy and 17.9{\%} had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0{\%} and 45.6{\%}, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001). ● CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.",
keywords = "Anti-vascular endothelial growth factor therapy, Photodynamic therapy, Ranibizumab, Treatment patterns",
author = "Mohamad, {Nur Afiqah} and Vasudevan Ramachandran and Patimah Ismail and {Mohd Isa}, Hazlita and Chan, {Yoke Mun} and Ngah, {Nor Fariza} and {Md Bakri}, Norshakimah and Ching, {Siew Mooi} and Hoo, {Fan Kee} and {Wan Sulaiman}, {Wan Aliaa}",
year = "2017",
month = "12",
day = "18",
doi = "10.18240/ijo.2017.12.16",
language = "English",
volume = "10",
pages = "1889--1897",
journal = "International Eye Science",
issn = "2222-3959",
publisher = "Press of International Journal of Ophthalmology",
number = "12",

}

TY - JOUR

T1 - Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia

AU - Mohamad, Nur Afiqah

AU - Ramachandran, Vasudevan

AU - Ismail, Patimah

AU - Mohd Isa, Hazlita

AU - Chan, Yoke Mun

AU - Ngah, Nor Fariza

AU - Md Bakri, Norshakimah

AU - Ching, Siew Mooi

AU - Hoo, Fan Kee

AU - Wan Sulaiman, Wan Aliaa

PY - 2017/12/18

Y1 - 2017/12/18

N2 - ● AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. ● METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. ● RESULTS: The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001). ● CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.

AB - ● AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. ● METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. ● RESULTS: The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001). ● CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.

KW - Anti-vascular endothelial growth factor therapy

KW - Photodynamic therapy

KW - Ranibizumab

KW - Treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=85037592876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037592876&partnerID=8YFLogxK

U2 - 10.18240/ijo.2017.12.16

DO - 10.18240/ijo.2017.12.16

M3 - Article

AN - SCOPUS:85037592876

VL - 10

SP - 1889

EP - 1897

JO - International Eye Science

JF - International Eye Science

SN - 2222-3959

IS - 12

ER -